Content by Netherlands Cancer Institute

|2 min read

New Approach to Using Immunotherapy Combinations in Bladder Cancer

Nivolumab and gemcitabine–cisplatin combo showed significantly better outcomes than standard-of-care in patients with advanced urothelial carcinoma
Page 1 of 1